Top Markets
#1 Status Status +19.34%
#2 FGRS (Figure Tokenized Stock) FGRS (Figure Tokenized Stock) +18.51%
#3 GoPlus Security GoPlus Security +14.26%
#4 Ontology Gas Ontology Gas +12.27%
#5 DMT-NAT DMT-NAT +8.99%
#6 Nillion Nillion +7.04%
#7 Provenance Blockchain Provenance Blockchain +7.02%
#8 Janction Janction +6.49%
#9 Cap Cap +6.34%
#10 Bedrock Bedrock +5.75%
Coin of the day
Status Status
Ustawienia
Język
POLSKI
Waluta
USD
Motyw
Renalytix Plc Renalytix Plc

Renalytix Plc

RNLX
Pozycja w akcjach #33998
Renalytix Plc, established in New York in 2018 and known as Renalytix AI plc... Renalytix Plc, established in New York in 2018 and known as Renalytix AI plc until its name change in June 2021, focuses on creating artificial intelligence-driven in vitro diagnostic tools for kidney ailments. Its primary product, KidneyIntelX, is an advanced diagnostic system that utilizes an AI-powered algorithm. This algorithm integrates multiple data sources, including scientifically validated blood markers, genetic predispositions, and individual patient information from electronic health records, to produce a distinct risk score for kidney disease. The company's technology is applied in various areas: identifying and predicting the course of kidney disease, informing clinical treatment, selecting patients for pharmaceutical trials, and discovering new therapeutic targets. Renalytix has formed several strategic collaborations, such as licensing agreements with Mount Sinai Health System for AI-assisted kidney disease diagnosis, with Joslin Diabetes Center, Inc. for developing biomarker-based kidney disease prediction products, and with Kantaro Biosciences LLC for laboratory tests to detect SARS-CoV-2 antibodies. Furthermore, it has partnered with Atrium Health, Wake Forest Baptist Health, and Wake Forest School of Medicine to introduce an innovative clinical care model aimed at improving kidney health outcomes and preventing disease advancement and failure in vulnerable populations.
Cena akcji
$0.1502
Ostatnia synchronizacja: 2024-11-04
Kapitalizacja rynkowa
$6.43M
Zmiana (1 dzień)
-5.45%
Zmiana (1 rok)
0.00%
Kraj
US
Handel Renalytix Plc (RNLX)

Kategoria

Healthcare
Przychody dla Renalytix Plc (RNLX)
Przychody w Sep 2024 TTM: $2.35M
Według najnowszych raportów finansowych Renalytix Plc, obecny przychód firmy (TTM) wynosi $2.35M. W roku 2023 firma osiągnęła przychód w wysokości $3.40M wzrost w porównaniu do przychodu z roku 2022, który wynosił $2.97M. Przychód to całkowita kwota dochodu generowana przez firmę ze sprzedaży towarów lub usług. W przeciwieństwie do zysku, nie są odliczane żadne koszty.
Historia przychodów firmy Renalytix Plc od 2018 do 2026
Przychody na koniec każdego roku
Rok Przychody Zmień
2026 (TTM) $2.35M 2.75%
2024 $2.29M -32.74%
2023 $3.40M 14.58%
2022 $2.97M 99.20%
2021 $1.49M 0.00%
2020 0.00 0.00%
2019 0.00 0.00%
2018 0.00 0.00%
Przychody podobnych firm lub konkurentów
Firma Przychody Różnica w przychodach Kraj
GE HealthCare Technologies Inc. GE HealthCare Technologies Inc.
GE HealthCare Technologies Inc.
GEHC.US
 $20.24B 860,571.77%
US
Pro Medicus Limited Pro Medicus Limited
Pro Medicus Limited
PME.AX
 $160.46M 6,722.29%
AU
BrightSpring Health Services, Inc. Common Stock BrightSpring Health Services, Inc. Common Stock
BrightSpring Health Services, Inc. Common Stock
BTSG.US
 $14.37B 610,937.33%
US
Tempus AI, Inc. Tempus AI, Inc.
Tempus AI, Inc.
TEM.US
 $1.43B 60,785.16%
US
Signify Health, Inc. Signify Health, Inc.
Signify Health, Inc.
SGFY.US
 - -
US